Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study
{{output}}
Background: Management of non-small cell lung cancer (NSCLC) after acquired resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is an unmet clinical need with no consensus on opt... ...
